Furthermore, marked inter- and intra-patient MM heterogeneity in terms of tumor suppressor gene status was also evident in freshly derived cell lines, highlighting the need for careful pre-evaluation of the suitability of MM cell-based models used in pre-clinical testing of agents targeting p16, p53, Merlin and related pathways. This evidence concerns the gene NF2 and Miyoshi myopathy.